Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.5
(2.6%)
USD 24.5
(2.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 343.96 Million USD | 38.22% |
| 2022 | 248.86 Million USD | 24.59% |
| 2021 | 199.73 Million USD | 39.35% |
| 2020 | 143.34 Million USD | 8.65% |
| 2019 | 131.92 Million USD | 23.31% |
| 2018 | 106.98 Million USD | 17.83% |
| 2017 | 90.79 Million USD | -12.86% |
| 2016 | 104.18 Million USD | 34.7% |
| 2015 | 77.34 Million USD | 50.9% |
| 2014 | 51.25 Million USD | -41.06% |
| 2013 | 86.95 Million USD | -3.71% |
| 2012 | 90.3 Million USD | 221.32% |
| 2011 | 28.1 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 87.29 Million USD | -6.71% |
| 2024 Q2 | 92.04 Million USD | 5.45% |
| 2023 Q2 | 72.73 Million USD | -1.49% |
| 2023 Q3 | 108.4 Million USD | 49.03% |
| 2023 Q4 | 93.56 Million USD | -13.69% |
| 2023 Q1 | 73.84 Million USD | 3.75% |
| 2023 FY | 343.96 Million USD | 38.22% |
| 2022 Q4 | 71.16 Million USD | 21.63% |
| 2022 Q1 | 55.82 Million USD | -0.73% |
| 2022 Q2 | 63.35 Million USD | 13.49% |
| 2022 Q3 | 58.51 Million USD | -7.65% |
| 2022 FY | 248.86 Million USD | 24.59% |
| 2021 Q1 | 44.94 Million USD | 22.03% |
| 2021 Q4 | 56.23 Million USD | 9.87% |
| 2021 Q3 | 51.18 Million USD | 8.04% |
| 2021 FY | 199.73 Million USD | 39.35% |
| 2021 Q2 | 47.37 Million USD | 5.41% |
| 2020 Q4 | 36.83 Million USD | 0.89% |
| 2020 Q2 | 33.17 Million USD | -9.9% |
| 2020 Q3 | 36.5 Million USD | 10.04% |
| 2020 FY | 143.34 Million USD | 8.65% |
| 2020 Q1 | 36.82 Million USD | 10.31% |
| 2019 Q1 | 30.9 Million USD | -10.91% |
| 2019 Q3 | 35.25 Million USD | 8.85% |
| 2019 FY | 131.92 Million USD | 23.31% |
| 2019 Q4 | 33.38 Million USD | -5.31% |
| 2019 Q2 | 32.38 Million USD | 4.8% |
| 2018 Q2 | 26.15 Million USD | 53.31% |
| 2018 FY | 106.98 Million USD | 17.83% |
| 2018 Q4 | 34.68 Million USD | 18.55% |
| 2018 Q3 | 29.26 Million USD | 11.87% |
| 2018 Q1 | 17.06 Million USD | -17.1% |
| 2017 Q1 | 22.82 Million USD | 14.36% |
| 2017 Q4 | 20.57 Million USD | -0.3% |
| 2017 Q3 | 20.64 Million USD | -22.83% |
| 2017 Q2 | 26.74 Million USD | 17.17% |
| 2017 FY | 90.79 Million USD | -12.86% |
| 2016 FY | 104.18 Million USD | 34.7% |
| 2016 Q4 | 19.96 Million USD | -27.71% |
| 2016 Q3 | 27.61 Million USD | -12.93% |
| 2016 Q2 | 31.71 Million USD | 27.36% |
| 2016 Q1 | 24.9 Million USD | -24.93% |
| 2015 Q1 | 13.28 Million USD | 11.03% |
| 2015 FY | 77.34 Million USD | 50.9% |
| 2015 Q4 | 33.17 Million USD | 88.71% |
| 2015 Q3 | 17.57 Million USD | 31.99% |
| 2015 Q2 | 13.31 Million USD | 0.29% |
| 2014 Q1 | 12.5 Million USD | -36.28% |
| 2014 Q2 | 14.99 Million USD | 19.89% |
| 2014 FY | 51.25 Million USD | -41.06% |
| 2014 Q4 | 11.96 Million USD | 1.44% |
| 2014 Q3 | 11.79 Million USD | -21.37% |
| 2013 FY | 86.95 Million USD | -3.71% |
| 2013 Q1 | 19.55 Million USD | -10.17% |
| 2013 Q2 | 27.48 Million USD | 40.56% |
| 2013 Q3 | 20.28 Million USD | -26.23% |
| 2013 Q4 | 19.62 Million USD | -3.21% |
| 2012 FY | 90.3 Million USD | 221.32% |
| 2012 Q4 | 21.77 Million USD | 0.0% |
| 2011 FY | 28.1 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -12.664% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -1056.117% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -5.457% |
| Cosmos Health Inc. | 4.34 Million USD | -7808.094% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 14371.489% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -370.757% |
| Cronos Group Inc. | 6.99 Million USD | -4820.228% |
| Incannex Healthcare Limited | 12 Thousand USD | -2866300.0% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 113620.792% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -721.907% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 46233.79% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -4024.727% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -4024.727% |
| SCYNEXIS, Inc. | 124.51 Million USD | -176.242% |
| Safety Shot Inc | -74.45 Thousand USD | 462068.653% |
| Theratechnologies Inc. | 62.12 Million USD | -453.635% |
| Alpha Teknova, Inc. | 10.29 Million USD | -3240.793% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -3313.099% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 29.847% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -7149.062% |
| Dynavax Technologies Corporation | 182.11 Million USD | -88.872% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 22.031% |
| Radius Health, Inc. | 307.71 Million USD | -11.783% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -61991.337% |
| Alvotech | -69.42 Million USD | 595.474% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 20.124% |
| SIGA Technologies, Inc. | 122.09 Million USD | -181.728% |
| Shineco, Inc. | 882.16 Thousand USD | -38891.213% |
| Silver Spike Investment Corp. | 8.1 Million USD | -4145.156% |
| Journey Medical Corporation | 52.52 Million USD | -554.915% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -8106.972% |
| Embecta Corp. | 749.9 Million USD | 54.131% |
| Harrow Health, Inc. | 90.55 Million USD | -279.853% |
| Procaps Group, S.A. | 239.56 Million USD | -43.578% |
| Biofrontera Inc. | 16.62 Million USD | -1968.732% |
| DURECT Corporation | 6.83 Million USD | -4935.397% |
| PainReform Ltd. | -15 Thousand USD | 2293220.0% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 34.325% |
| OptiNose, Inc. | 62.35 Million USD | -451.637% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -11162.23% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -11.033% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -927.203% |
| ProPhase Labs, Inc. | 16.23 Million USD | -2018.16% |
| Phibro Animal Health Corporation | 312.48 Million USD | -10.074% |
| Procaps Group S.A. | 239.56 Million USD | -43.578% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -26318.433% |
| Viatris Inc. | 6.43 Billion USD | 94.658% |
| Rockwell Medical, Inc. | 8.7 Million USD | -3851.838% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -530.14% |
| Tilray Brands, Inc. | 223.35 Million USD | -54.003% |
| PetIQ, Inc. | 252.74 Million USD | -36.096% |
| Talphera, Inc. | -4.89 Million USD | 7126.925% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 81.381% |
| Alimera Sciences, Inc. | 61.17 Million USD | -462.315% |
| Assertio Holdings, Inc. | 125.04 Million USD | -175.067% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 5050283.527% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1168.459% |
| Hempacco Co., Inc. | -1.21 Million USD | 28390.727% |
| Alvotech | -69.42 Million USD | 595.474% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 51.523% |
| Kamada Ltd. | 52.59 Million USD | -554.022% |
| Currenc Group, Inc. | 17.35 Million USD | -1881.804% |
| Indivior PLC | 907 Million USD | 62.076% |
| Evoke Pharma, Inc. | 4.97 Million USD | -6808.721% |
| Flora Growth Corp. | 17.73 Million USD | -1839.159% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 14371.489% |
| Evolus, Inc. | 140.52 Million USD | -144.772% |
| HUTCHMED (China) Limited | 453.55 Million USD | 24.161% |
| Akanda Corp. | 111.44 Thousand USD | -308532.648% |